IVF Devices and Consumables Market Size

Global IVF Devices and Consumables Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.33 billion in 2024 to USD 13.5 billion by 2032, growing at a CAGR of 19.1% during the forecast period (2025-2032). 

The global IVF devices and consumables industry is growing due to the prevalence of infertility coupled with delayed pregnancies, which arise from lifestyle change and aging.

The global IVF devices and consumables market has experienced significant growth due to advances in assisted reproductive technologies (ART) and an increasing number of individuals and couples seeking fertility treatments. IVF involves fertilizing an egg outside the body and then implanting the fertilized embryo in the uterus. The global IVF devices and consumables market, therefore, comprises both devices used in the IVF process and consumables used, which includes culture media, catheters, and needles. The driving factors behind this market are rising cases of infertility, delayed pregnancies, and changed lifestyles, among other factors. Acceptance of fertility treatments across the globe has increased.

Technological advancements have been a critical driver of market expansion, with innovations in IVF equipment such as incubators, embryo culture systems, ultrasound systems, and cryopreservation systems enhancing the success rates of IVF procedures. The advanced consumables of IVF, which include culture media, sperm-processing kits, and embryo transfer catheters, also have improved the outcomes, driving the market even further. More focus on individualized IVF treatments and more advanced diagnostic tools have improved the care of the patients and therefore the success rate.

Increasing fertility clinics and healthcare infrastructure in emerging markets in recent times, rising fertility clinics and growing healthcare infrastructure within emerging markets have contributed to the current growth of the market. As the demand for IVF procedures will persist, the demand for advanced IVF devices and consumables should also remain high as governments provide support through policies and coverage of health insurance for fertility treatments.

Acceptance of ART in society and integration into mainstream healthcare systems are factors that are fueling the global IVF devices and consumables market. The trends of increasing single parenthood, the desire of LGBTQ+ couples to undergo IVF services, and the aging population create a need for IVF solutions, thus creating a momentum in the market. This sector will continue to carry out investments in research and development, thus setting it up for added innovations and expansion in the coming years.

Key Market Attributes

In December 2024, CooperSurgical, one of the major providers of women's health solutions, launched its new range of advanced IVF devices that come with AI support for embryo assessment. These systems use AI, with the primary purpose of more accurate embryo selection and, hence, better IVF treatment results. This will dramatically make the IVF process smoother and the cost per cycle cheaper, hence opening IVF up to a larger group of patients in the next years, especially in developing countries with increasing health care infrastructure.

In November 2024, Vitrolife, one of the leaders in the IVF consumables market, unveiled its new and improved embryo culture media, developed for specific patient needs. Enhanced media formulations are designed to increase embryo viability and optimize culture conditions, thus improving the success rate of IVF procedures. Over the next 4-5 years, these are expected to considerably impact IVF success rates since there is increasingly high demand for high-quality consumables. Over the next decade, this shall pave the way for more personal treatment and develop the market within both developed and emerging economies.

Merck Group invested in the development of next-generation IVF equipment integrating CRISPR gene-editing technology for embryo screening. The breakthrough reduces the risks of genetic disorders through more accurate genetic testing for embryos, and it happened in September 2024. Such advances in genetic screening will thus propel the transformation of the IVF market for the next ten years, through safer and effective treatments, that meet the needs of a world where genetic testing and fertility are on the upsurge globally.

In August 2024, Ferring Pharmaceuticals released a new product line for consumables in IVF that provides individualized hormone therapy solutions with an aim of increasing embryo implantation rates. Such products will transform the course of IVF treatment protocols within the next ten years with a robust support system through comprehensive clinical trials. As personalized medicine keeps gaining grounds, these developments are likely to continue driving substantial growth in the market, especially as markets become concentrated on advanced reproductive technologies to make IVF ever more precise, accessible, and affordable in the future.